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MicroarrayGenome-wide gene expression proﬁling was carried out on rat hepatoma cells and compared to proﬁles of
hepatoma “variant” cell lines derived via a stringent selection protocol that enriches for rare cells (b1 in
100,000 cells) that fail to drive liver function. Results show 132 genes that are strongly (>5-fold) repressed
in each of the four variant cell lines tested. An additional 68 genes were repressed in 3 of 4 variant cell lines.
Importantly, several of the repressed genes are members of transcriptional activation pathways, suggesting
that they may contribute to maintaining the hepatic phenotype. Ectopic expression of the HNF1A gene in a
variant cell line resulted in activation of 56 genes, 37 of which were included in the repressed data set.
These data suggest that a high level of reprogramming occurs when hepatoma cells convert to a non-
differentiated phenotype, a process that can be partially reversed by the introduction of transcription factors.
© 2012 Elsevier Inc. All rights reserved.1. Introduction
Genetic programs involved in the establishment and maintenance of
liver-speciﬁc gene expression have been identiﬁed, yet the contribution
and interplay of these pathways leading to and maintaining the differ-
entiated state remain unclear. Regulatory circuitry within mammalian
hepatocytes has been mapped and includes several master regulatory
genes that encode proteins which bind to and activate liver-speciﬁc
genes. These hepatocyte-enriched factors include a homeodomain pro-
tein (HNF1α), a winged helix factor (FOXA2/HNF3β), an orphan nuclear
receptor (HNF4), and a onecut homeodomain protein (ONECUT1/HNF6)
[1–4]. These factors appear to act synergistically to activate expression
of hundreds of hepatic genes [4]. Many of these factors operate in
autoregulatory loops to activate expression of each other [4–6]. Addi-
tional regulatory circuitry has also been mapped in hepatocytes [7–9].
Unfortunately, the identiﬁcation and role of additional genetic networks
that determine hepatic identity has remained elusive.
Analysis of cultured hepatoma cell lines and their dedifferentiated
derivatives have long provided information regarding molecular
pathways involved in repression and activation of liver-speciﬁc
gene expression [6,10–13]. Previous studies have shown that stable
transfection of transcription factors HNF4 or HNF1α into certain hep-
atoma variant cell lines (M38 and H11 cells) resulted in re-activation
of the silenced α1AT (Serpina1) gene and other hepatic genes, but in-
troduction of these factors into other variant cell lines (HS2 or M29
cells) failed to rescue hepatic function [5,14,15], suggesting that
these variant cell lines may have distinct defects. Fusion of various
combinations of variant cell lines failed to establish complementationrights reserved.groups, indicating that although defects may be distinct, common
regulatory pathways are impacted.
Extensive remodeling of chromatin has been shown around the
Serpina1 locus by ectopic expression of HNF1α in the H11 cells
[16,17], suggesting that single transcription factors can lead to remodel-
ing of large regions of DNA. Importantly, hepatic gene expression could
be rescued in one such variant cell line, M38, by introduction of human
chromosome 12 [18], although it was not possible to identify the locus
on chromosome 12 responsible for the rescue event. Previous studies
on hepatoma variant cells were limited to a gene-by-gene analysis.
Thus, additional characterization of these cells via whole genome proﬁl-
ing was merited in order to identify the extent of genomic repro-
gramming that occurred in the variant cell types as well as to uncover
candidate genes responsible for maintaining the hepatic phenotype.
In order to identify gene products that may play a key role in initiat-
ing and/or maintaining the liver phenotype, we proﬁled genome-wide
expression in hepatoma cells and hepatoma-derived variant cell lines.
Our strategy was to compare gene expression proﬁles of a hepatoma pa-
rental cell line with that of a panel of 4 independently derived hepatoma
variant cell lines. Our goal was to determine the full extent of repro-
gramming that occurs in the variant cell types leading to loss of hepatic
function as well as to identify candidate genes that are responsible for
maintaining regulatory circuitry controlling liver function.
2. Materials and methods
2.1. Cell lines and culture conditions
All cell lines described are derived from the rat liver tumor line
H4IIEC3. Fg14 cells are an adenine phosphoribosyltransferase-positive
(APRT+), xanthine–guanine phosphoribosyltransferase-positive (GPT+)
cell line derived from the APRT− and hypoxanthine–guanine
177G.A. Bulla et al. / Genomics 100 (2012) 176–183phosphoribosyltransferase-negative (HPRT−) Fado-2 cells by stable
transfection of Gpt and Aprt transgenes driven by the human
α1-antitrypisin (α1AT, SERPINA1) gene promoter (−640 to −2 bp).
Dedifferentiated cell lines, including M29, H11, HS2 and M38 cells,
were derived from the Fg14 cells by negative selection against both
Aprt and Gpt transgene gene expression using 20 μg/ml 2,6-
diaminopurine (DAP) and 30 μg/ml 6-thioxanthine, respectively [19].
M29 and M38 cells have a reversion rate to APRT+ of approximately
10−5, while the H11 cells revert at a frequency of 10−3 and HS2 cells at
b10−8. All cells were maintained in 1:1 Ham's F12/Dulbecco's modiﬁed
Eagle's medium (FDV) containing 5% fetal bovine serum (FBS) (Gibco)
and 5 μg/100 ml penicillin–streptomycin (Gibco) at 37 °C in a humid 5%
CO2 chamber.
2.2. RNA extraction
RNA was extracted from nearly-conﬂuent monolayers using a
Qiagen RNeasy Mini Kit (Cat #74104) following the kit protocol
with the addition of a DNaseI (Cat #79254) digestion step, as per pro-
tocol. Brieﬂy, approximately 107 cells were lysed with RLT buffer,
samples spun through a Qiagen column shredder to ensure homoge-
nization, and RNA collected on an RNEasy column. Samples were
washed and then digested with DNase I for 15 min at RT. RNA was
further washed then eluted. RNA integrity was determined by 28S
and 18S rRNA visualization following gel electrophoresis in MOPS
with 1% agarose-2.2 M formaldehyde gels, as described [20]. RNA pu-
rity and concentration were determined by nano-drop spectropho-
tometry at 260 and 280 nm. Triplicate samples of RNA extracted
from independent cultures of each cell line (with the exception of
the M29 cells) were used for microarray analysis.
2.3. Microarray analysis
For Illumina microarray analysis, samples were prepared and ana-
lyzed by the W. M. Keck Center for Comparative and Functional Geno-
mics in the Roy J. Carver Biotechnology Center at the University of
Illinois at Urbana-Champaign. RNA quality was determined using the
Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). Brieﬂy,
300 ng of high quality total RNAwere primed with an oligo(dT) primer
bearing a T7 promoter, and reverse transcribed in the ﬁrst-strand cDNA
synthesis using the Illumina Total Prep RNA Ampliﬁcation Kit (Ambion,
Inc., Austin, TX). Single stranded cDNA was then converted into double
stranded cDNA according to the manufacturer's instructions. The
double-stranded cDNA was puriﬁed and served as a template in the
14-hour in vitro transcription (IVT) reaction. Prior to hybridization,
the synthesized biotin labeled cRNA was cleaned up using the same
Ampliﬁcation Kit. After the quality control assessment, 750 ng of
cRNA from each experimental sample along with hybridization con-
trols was hybridized for 16 h to the RatRef-12 v1 Expression BeadChips
(Illumina, Inc., San Diego, CA) in the 58 °C Illumina Hybridization Oven.
Washing, staining with streptavidin-Cy3 (GE Healthcare Bio-Sciences,
Piscataway, NJ), and scanning were performed according to the
Illumina Whole-Genome Gene Expression Direct Hybridization Assay
Guide (Part#11322355, Rev. A). Two BeadChips were used in this
study, each containing twelve arrays. The arrays were scanned using
an Illumina BeadArray Reader. Each array image was visually screened
to discount for signal artifacts, scratches or debris. The images were
analyzed using the GeneExpression Module (version 1.8.0) of the
Illumina GenomeStudio software.
2.4. Reverse transcription quantitative polymerase chain reaction
(RT-qPCR)
The standard two-step RT-PCR protocol in the MasterAmp High
Fidelity RT-PCR kit (Epicentre Biotechnologies) was used for the syn-
thesis of cDNA from puriﬁed RNA. Reverse transcription reactionswith the test RNA samples contained 19 μl sterile nuclease-free H2O,
3 μl RNA, 25 μl MasterAmp 2X RT-PCR PreMix, 2 μl Oligo DT and 1 μl
Moloney Murine Leukemia Virus Reverse Transcriptase (MMLV-RT).
The control mix contained 23 μl sterile nuclease-free H2O, 25 μl
MasterAmp 2X RT-PCR PreMix, 1 μl MMVL-RT, and 1 μl control mix.
The mixes were stored on ice before starting the reaction. Samples
were then incubated at 37 °C for 30 min, and qPCR was run using
the synthesized cDNA. All primer pairs used were complementary
to exonic sequences that spanned intronic regions in order to limit
the possibility of genomic DNA ampliﬁcation giving rise to false pos-
itive signals for RNA production.
The cDNA quality of each cell line was tested with the reference
gene Gapdh. Triplicate assays were used for each reaction and raw
threshold values (Ct) were averaged following ampliﬁcation. For the
test RNA, triplicates of 20 ng cDNA was added to 10 μl of Fast SYBR
Green (Applied Biosystems), 1 μl of a primer working stock containing
both forward and reverse (IDTDNA) with a concentration of ~50 μM
and 4 μl of RNase-free H2O (Qiagen). Primer sequences used for
RT-qPCR are as follows: Gapdh: for- 5′ tgattctacccacggcaagtt 3′, rev-
5′ tgatgggtttcccattgatga 3′; Alb: for- 5′ catcctgaaccgtctgtgtg 3′, rev- 5′
tttccaccaaggacccacta 3′; Fgb: for- 5′ gaccatccacaacggcatgt 3′, rev- 5′
cgccgccatcttcttttgag 3′; SerpinA1: for- 5′ cctataccgggagctggtccat 3′,
rev- 5′ ttgcgagtgtcacccttgct 3′; Hnf4a: for- 5′ tgagcctggaggattacatcaac
3′, rev- 5′ aactggatctgcatcatctg 3′; Hhex: for- 5′ aaaggaaaggcggtcaag-
tgaggt 3′, rev- 5′ atcttggccagacgctttctctca 3′; Wnt4: for- 5′ agaag-
ctcaaaggcctgatccaga 3′, rev- 5′ actggtattgcgactcctcaatgg 3′. The control
for the RT-qPCR contained 5 μl of RNase-free H2O, in place of cDNA,
10 μl of SYBR Green, 4 μl of RNase-free H2O and 1 μl of primer working
stock. The Applied Biosystems StepOne thermocycler was set for 40 cy-
cles with a denaturing temperature of 95 °C for 3 s and annealing/
extension temperatures at 5 °C above the Tm of the primers for 30 s.
Also, a ﬁnal melt curve step was performed at 95 °C for 15 s, down to
60 °C for 60 s and a ﬁnal step at 95 °C again for 15 s.
After ampliﬁcation, the raw Ct values were averaged for each
speciﬁc cell line. The ampliﬁed target genes in each hepatoma var-
iant were normalized to the respective Gapdh Ct‐value, generating
a delta-Ct value (Δ Ct). Fold difference in gene expression was de-
termined with a delta delta‐Ct (ΔΔ Ct) calculation. The Δ Ct of the
control cell line (Fg14) was subtracted from the hepatoma variant
Δ Ct value, generating a ΔΔ Ct value. Using a log base 2 scale,
the calculated difference was placed into the ΔΔ Ct equation:
2(ΔCt (sample a)− experimental)− (ΔCt− control).
2.5. Testing candidate genes for hepatic gene rescue
Expression vectors containing candidate genes (purchased from
Origene, Inc.) were introduced into the H11 variant cell line by lipo-
fection. Brieﬂy, plasmid DNA was mixed with the lipofection reagent
(Lipofectamine LTX with PLUS reagent; Invitrogen, Inc.) as per kit
protocol and incubated with freshly plated H11 cells in 6-well dishes.
After 8 h, the transfection mixtures were replaced with complete me-
dium. After 48 h, cells were split 1:20 into complete medium plus
50 μg/ml G418. After 2–3 weeks, G418 resistant clones were pooled
(10–50 clones per pool), expanded, and RNA extracted as described
above. RNA was reverse transcribed into cDNA for use in RT-qPCR.
In addition, pooled cells were plated into complete medium with
and without the addition of Adenine–Aminopterin–Thymidine
(AAT) to select for cells which had re-expressed the SERPINA1-Aprt
transgene. Finally, select RNAs were used for single Illumina whole
genome microarrays as described above and compared to triplicate
microarrays using RNA isolated from non-transfected H11 cells.
3. Results
Whole genome expression proﬁling of hepatoma variant cell lines
was carried out in order to identify pathways responsible for the loss
A
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178 G.A. Bulla et al. / Genomics 100 (2012) 176–183of liver function in these cells. Fg14 hepatoma cells and four previous-
ly characterized hepatoma variant cell lines (designated M29, HS2,
H11 and M38) derived from Fg14 cells have been previously de-
scribed [1,13–15,19]. These variant cell lines were derived, without
the use of mutagens, at a low frequency (~10−6) from Fg14 cells
based on their inability to drive expression of a SERPINA–Aprt trans-
gene (see Materials and Methods, Fig. 1). These hepatoma variant
cells are relatively stable, but have been shown to revert back to the
hepatoma phenotype at frequencies ranging from 10−3 to b10−8
(based on reactivation of the SERPINA1-Aprt transgene and a few
key liver-speciﬁc genes).
In order to determine viability of the whole-genome approach in
evaluating the loss of liver-speciﬁc gene expression in the cell vari-
ants, triplicate whole-genome microarray experiments were carried
out using RNA isolated from parental and variant cell lines. RNA was
reverse transcribed into cDNA, which was then transcribed into
RNA, labeled with biotin, and hybridized to the Illumina RatRef-12
v1Beadchips microarrays. The microarrays were then stained with
streptavidin-Cy3 and scanned for ﬂuorescence.
3.1. Microarray assay reproducibility
To examine reproducibility of the microarray assay, we compared
biological replicates for each cell line as well as variability for gene
targets within a single microarray (normally 25 to 70 replicate
beads per assay) using P value analysis. Results show that ﬂuorescent
values of ~100–200 units typically had P values of >0.05, while ex-
pression values for all genes examined further in the current study
(with a >5-fold reduction in expression comparing Fg14 to the vari-
ant cell types) showed P values of b0.001 in the hepatoma parental
line and had typical ﬂuorescent values of 200–30,000 units (results
not shown).
In order to normalize day-to-day variation being responsible for
changes in gene expression proﬁles, RNA was extracted from each
cell line on separate days. Analysis of microarray signals showed
that variation in signal strength for each control gene was less than
2-fold for housekeeping genes Actb and Gapdh across all arrays
(data not shown). Variability of expression among replicates was
then considered in order to estimate false positive rates. The ratio of
averaged gene expression across each set of three replicate arrays
was done for each cell line. We observed a modest number of genes
with >5-fold signal variability within replicates. Among the
~22,500 targets, the number of genes with signal strength that dif-
fered by >5-fold between replicates ranged from 0 to 5 genes for
the Fg14, H11 and M38 replicates, although 22 genes were identiﬁed
for the HS2 cells (Data not shown). Based on these data, we applied
two criteria when comparing average gene expression between hep-
atoma parental cells and the variant cell lines: 1) gene expression
values in the variant cell lines must show a >5-fold difference in av-
erage expression compared to parental cells and 2) this >5-foldGPT +
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Fig. 1. Derivation of hepatoma variant cell lines. Fg-14 cells contain two selectable
trans-genes under the control of the liver-speciﬁc human SERPINA1 (alpha-1 anti-
trypsin) gene promoter. Selection against expression of these genes resulted in the
production of hepatoma variant cell lines (e.g. HS2, M38, H11 and M29) which lack ex-
pression of several liver genes.difference must be shared by at least 2 of the four variant cell lines
tested. These criteria suggest a very low number of false positives
that could interfere with the analysis.3.2. Microarray validation
Validation of microarray results was carried out using reverse-
transcription quantitative PCR (RT-qPCR) on select genes. Expression
levels for several genes were normalized to Gapdh signals (which var-
ied by less than 2-fold) and comparisons between the Fg14 hepatoma
parental cells and the variant cells were made. Genes monitored in-
cluded those encoding transcriptional activation pathway proteins
(Wnt4, Hnf4a, Hnf1a and Hhex) and downstream genes (Alb, Fgb,
Serpina1). Representative samples from each of the cell line RNAs
tested were converted to cDNA and ampliﬁed in the presence of SYBR
Green. Triplicate reactions were done and ΔΔCT values determined.
The data shows strong repression of each of these genes across
most variant cell lines compared to those of the hepatoma parental
cells (Fig. 2B). In general, strong agreement was observed between
the fold differences observed in the microarray data (Fig. 2A) and
those derived from qPCR. However, the actual fold differences in the
qPCR tended to be much more robust, indicating that the microarray
data underrepresented the actual fold differences. This difference is
exaggerated in cases in which the hepatoma levels of ﬂorescence
are modest (see Table 2 for examples).
We also compared our microarray data sets with previously pub-
lished data from normal rat liver using the same Illumina RatRef-12
Expression BeadChips microarray assays [21] (kind gift of Lie Guo,
National Center of Toxicological Research, FDA) normalized to
Gapdh levels. As expected, the Fg14 tumor cells showed a large de-
gree of misregulated gene expression compared to the normal rat
liver, with ~1100 genes showing 5-fold differences in expression.
However, expression levels of Hnf4a, Hnf1a, Foxa1, Onecut1 and
Cebp were within 2-fold compared to the Fg14 cells (data not
shown).B
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Fig. 2. Comparison of microarray data and qPCR data. Fold repression in the hepatoma
variant cell lines compared to those in Fg14 hepatoma cells is shown for A) Microarray
analysis and B) qPCR analysis. Fold differences are shown on a Log10 scale. The upper
graph shows two orders of magnitude, while the lower graph shows 4 orders.
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Fig. 3. Gene repression in hepatoma variant cells. A. The number of genes with 5–10 fold, >10-fold and >100-fold repression levels (compared to Fg14 values) is shown for each
cell line. Each cell line showed similar gene repression proﬁles. B. The number of genes repressed >5-fold in all 4 hepatoma variant cell lines (center number), shared by 3 of 4 cell
lines (next set of values around center number), 2 of 4 cell lines and those unique to one cell line. A total of 355 genes were identiﬁed as >5-fold repressed in at least one cell line,
with 132 repressed in all four cell lines.
179G.A. Bulla et al. / Genomics 100 (2012) 176–1833.3. Analysis of gene repression in hepatoma variants
Genes that were repressed by >5-fold in the variant cells com-
pared to the Fg14 parental cells were assessed. Results show a large
number of genes that are strongly repressed in the variant cell lines.
Each of the variant cell lines showed a similar number of repressed
genes, with >5-fold repressed genes ranging from 221 to 281 genes
(Fig. 3A). Remarkably, a large number of >10-fold repressed genes
were also noted, ranging from 92 to 114 genes. Lastly, a small number
of genes (6–8) were repressed >100-fold in each cell line.
As described above, due to observed variability in expression values
between replicate samples, we asked which genes were repressed >5-
fold in at least two of four variant cell lines. A large number of genes
were identiﬁed (268 genes) that are repressed >5-fold in at least two
of the four variant cell lines tested (Fig. 3B). Of these, 50% (132) were re-
pressed in all four variant cell lines. Remarkably, 65 genes were re-
pressed >10-fold in all four variant cell lines (data not shown). In
addition, another 69 genes were shared between only two of the four
cell lines and 126 genes were repressed in only one cell line. Not surpris-
ingly, the majority of the unique genes were identiﬁed in the HS2 cells
(which showed the highest level of replicate variability) and M29 cells
(whose expression proﬁle was limited to a single microarray).
Of the 200 genes that were repressed >5-fold, many of these are
well-described markers of liver function, including Alb, Agt, Asl,
Aldob, Ass1, Pah, Fgg, Fgb, Hpx, Pah, Pck1, Tat, and Ttr. As expected,
because the human SERPINA1 promoter sequence was incorporated
into the selection strategy, the rat Serpina1 gene was also stronglyTable 1
Genes repressed >5-fold in 3 of 4 hepatoma variant cell lines. Of the 200 targets identiﬁed
ABCC2⁎ BHMT⁎ CYP2B15⁎ FBP2 H
ABCG5⁎ C2⁎ CYP2C23⁎ FETUB⁎ H
ADH⁎ C3⁎ CYP2C6 FGB⁎ H
ADM2⁎ C4BPA⁎ CYP2D2⁎ FGG⁎ H
AGMAT⁎ C4BPB CYP2D5 FMO1⁎ H
AGT⁎ C5 CYP2E1⁎ FUT2 H
AGXT2 C9⁎ CYP2F4 G6PC⁎ H
AHSG⁎ CCND1 CYP3A18⁎ GC⁎ H
AKR7A3 CDH17⁎ CYP4F1⁎ GCLM I
ALB CESL1 CYP8B1⁎ GLIPR1 I
ALDH1A7 CFI⁎ DEPDC7 GNG11 I
ALDOB⁎ CHDH DIO1 GPD1 K
AMT⁎ CPA1 ELA1 GPT⁎ K
ANG1 CPN1 ENPP3 GPX3 K
APON⁎ CREB3L3⁎ EPHX1⁎ GSTA2⁎ L
AQP11 CRYAB F2⁎ GULO L
AQP8 CTH FABP1⁎ GYS2 L
ASL CTRC FAM25A⁎ HAAO⁎ L
ASS CXCL11 FBLIM1 HAL⁎ L
BAAT CYP17A1⁎ FBP1⁎ HAMP⁎ M
⁎ Average repression level >10-fold.repressed in each of the four cell lines, as were other genes in the
same serine protease gene cluster such as Serpina6 and Serpina10.
Other repressed gene families included 11 CYP genes, and 7 members
of the UDP glycosyltransferase gene superfamily (Table 1).
3.4. Transcription factor silencing
Previous reports have clariﬁed the role of core transcriptional reg-
ulatory proteins in driving hepatic gene expression [2–4]. Four master
regulators in human hepatocytes have been identiﬁed, including
Hepatocyte Nuclear Factors HNF1α, HNF3β (FOXA2), HNF4 and
ONECUT1 (HNF6). Combined chromatin immunoprecipitation and
microarray analysis was used to show that these factors operate com-
binatorially to activate hepatic gene expression, each binding to
800–4000 gene promoters [4]. Due to loss of expression of several he-
patic genes, and based on previous results analyzing variant cells, we
expected these transcription factor genes to be repressed in the cell
variants. Unexpectedly, Hnf1a, Hnf4a, and Cebpa showed only modest
levels of repression (2-to 4.5 fold) and Foxa2 showed no repression.
Only Hnf6 (Onecut1) showed a strong repression proﬁle (Table 2).
3.5. Identiﬁcation of candidate genes
To identify candidate genes, we required that two criteria were
met: 1) >5-fold repression of gene expression in 2 of 4 variant cell
lines compared to those levels in the parental Fg14 cells and 2) the, only those with identiﬁed genes or LOC numbers (157 total) are shown.
HEX MAOB REEP6 TFPI⁎
MGCS2⁎ MDK RNASE4⁎ THPO
NRPAB METTL7B S100G⁎ TMEM176B⁎
PN MTTP⁎ SEC16B TTR
PX⁎ MUCDHL⁎ SECTM1 UGT1A1⁎
RSP12 OASL SELENBP1⁎ UGT2B⁎
SD17B13⁎ ONECUT1⁎ SERPINA1⁎ UGT2B17
SD17B2 OPLAH SERPINA10⁎ UGT2B36⁎
GFBP1⁎ PAH⁎ SERPINA3N UGT2B36
TIH3 PCK1⁎ SERPINA6⁎ UGT2B37⁎
TM2A PCSK6 SERPINC1⁎ UGT2B5⁎
MO⁎ PCSK9 SERPING1 LOC688266
NG1⁎ PLG SLC16A6 LOC691259⁎
RT8⁎ PON1⁎ SLC17A1⁎
CAT PPP1R14A SLC22A7
GALS2⁎ PTGDS SOAT2⁎
GALS4⁎ PTGR1 SPR
INCR PZP⁎ SSTR2
IPC⁎ QPRT⁎ SULT1B1
AF RBP1⁎ TAT⁎
Table 2
Expression levels of transcription factors in the Fg14 cells and variant cell lines as de-
termined by microarray data. Average signals obtained for Fg14 and H11 cells for a
set of liver-enriched transcription factors are shown. In addition, fold differences in ex-
pression values are given for each cell line.
Average values Fold repression
Transcription factor Fg14 H11 M38 H11 HS2 M29
Cebpa 250.0 100.7 2.1 2.5 1.5 2.1
Foxa2 3417.9 5632.0 0.6 0.6 1.1 1.1
Hnf1a 455.2 107.7 3.4 4.2 4.5 4.2
Hnf4 247.0 88.6 2.9 2.8 2.9 2.7
Onecut1 2011.9 134.6 10.7 14.9 5.3 16.9
180 G.A. Bulla et al. / Genomics 100 (2012) 176–183known or proposed function of the gene product inﬂuences transcrip-
tion (either as a transcription factor or is a member of a signaling
pathway that alters transcription). Of the 268 genes that met the
ﬁrst criteria, 19 of the genes identiﬁed were of unknown function.
We identiﬁed 14 genes that ﬁt these criteria (Table 3).
Importantly, several of the identiﬁed genes are members of tran-
scriptional activation pathways, suggesting that they contribute to
maintaining the hepatic phenotype. Repressed genes include liver-
enriched factors (Hhex, Onecut1), two developmental pluripotency-
associated genes (Dppa4 and Dppa5), Creg1 (cellular repressor of
E1A-stimulated genes), Creb3L3 (cAMP responsive element binding
protein 3-like 3), and Tcfap2b (AP-2 beta), which has been reported
to regulate the expression of genes required for development of ecto-
dermal tissues. These data suggest that a high level of reprogramming
occurred in variant cells, leading to a dramatic loss of liver‐speciﬁc
gene expression as well as activation of a smaller set of genes.
3.6. Forced expression of HNF1α in H11 variant cells partially rescues the
hepatic phenotype
We next tested several candidate genes for their ability to restore
hepatic gene expression. As a ﬁrst approach, we asked whether the
SERPINA1-aprt transgene (used to select the variants) was reacti-
vated, allowing survival in AAT selective medium. Of the eight genes
tested (Onecut1, Hnf1a, Igfbp1, Hhex, Creb3l3, Dppa4, Mdk and
Creg1), only Hnf1a-transfected cells survived in AAT selection
(Fig. 4A), in agreement with previously published data 19. qPCR
analysis veriﬁed that Hnf1a expression was increased 100-fold to
levels observed in the original hepatoma cells. Elevated levels of
Fgb, Hhex, and Serpina1 RNA were also observed (Fig. 4B). Single
whole genome microarray analysis of the Hnf1a-transfected cells
was compared to triplicate H11 data. Remarkably, 56 genes were
found to be activated at least 3 fold in the Hnf1a transfected cells
that were not activated in H11 cells transfected with control genes
(Fig. 4C). Promoter analysis using Genecard analysis indicates thatTable 3
List of candidate genes identiﬁed from list of repressed genes.
Fold repression Gene name De
M38 HS2 H11 M29
6.2 1.7 3.6 5.5 BHLHB2 Ba
12.9 15.0 14.6 13.7 CREB3L3 cA
3.6 6.4 2.7 5.9 CREG E1
17.4 18.7 18.7 16.7 DPPA4 De
12.2 11.9 11.9 10.1 DPPA5 Sim
9.3 8.5 7.9 8.8 GAS2 Gr
5.1 6.0 2.8 5.8 HHEX He
118.6 128.0 131.9 107.4 IGFBP1 In
8.3 9.6 0.1 7.4 MDK M
10.7 5.3 14.9 16.9 ONECUT1 On
7.0 14.9 2.1 43.3 RNF125 Ri
9.4 10.3 10.6 5.3 SEC16b SE
19.1 19.7 19.7 19.0 STRA8 St
3.5 9.5 1.0 21.0 TCFAP2B Tr30 (67%) of the genes for which promoter sequences are known (45
genes known, 11 unknown) contain HNF1α binding sites (Fig. 4C).
Not unexpectedly, the majority (37 of 56) of genes were identiﬁed
in our original analysis of gene repression in the variant cells, with
12 of the remaining genes being expressed at modest levels (b500
units) in the Fg14 cells, precluding identiﬁcation using our stringent
5-fold cut-off.
3.7. Comparison of gene proﬁles with that of hepatoma×ﬁbroblast whole
cell hybrids
Genome-wide repression of liver-speciﬁc gene expression in
hepatoma×ﬁbroblast somatic cell hybrids was recently reported [22].
We compared repression proﬁles of the cell hybrids with that of the
hepatoma variant cell lines in the current study with regard to candi-
date genes identiﬁed. Three candidate genes (Hhex, Igfbp1, and
Onecut) were identiﬁed in both data sets, but themajority of candidate
genes were non-overlapping. Both data sets showed 3–4 fold repres-
sion of transcription factors Hnf4a and Hnf1a, a level of repression
that did not meet the 5-fold cutoff used in this study (Fig. 5).
4. Discussion
Dedifferentiated hepatoma cells have long been studied in order
to deﬁne pathways that determine liver identity [6,12,23–25]. The
hepatoma variants used in this study were selected based on their in-
ability to drive the human SERPINA1 promoter fused to selectable
marker genes Aprt and Gpt [19]. These cells have been reported to
lack expression of Hnf1a and Hnf4a as well as several downstream
genes [1,14,18]. Also, defective apoptotic signaling has been observed
in these cells [24,26]. As expected from previous reports [14,15,18],
the rat Serpina1 gene was strongly repressed (55–90-fold) in each
of the variant cell lines tested compared to the parental Fg14 cells.
Unexpectedly, Hnf1a and Hnf4a (encoding transcription factors
reported to activate Serpina1 expression), did not meet our criteria
of 5-fold repression, instead showing a modest 3 to 4-fold repression.
This is likely due to the low level expression of (300–400 units) of
these factors in the hepatoma parental cells as measured by the
microarrays. Because signal to noise levels in the microarray ap-
proach 100 units, fold differences would be expected to be muted. In-
deed, qPCR analysis of relative expression levels showed a ~100-fold
reduction in expression of these genes. Thus we conclude that our
criteria may not be optimal when considering genes expressed at
low levels, and we likely failed to detect some candidate genes
using the 5-fold repression criteria.
We observed very little variability in expression levels when com-
paring replicate microarrays for some cell lines (Fg14, H11, M38), but
substantial variability in the HS2 replicates. This latter variabilityscription
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cells (a false positive rate of 20 genes expected from replicate analy-
sis). Indeed, HS2 cells showed 48 unique repressed genes, compared
to 4 and 25 unique genes in the M38 and H11 cells, respectively. Like-
wise, because we had only one sample of M29 cells, we expected ahigher false positive rate (though it could not be measured directly).
Indeed, the M29 cells had 51 repressed genes identiﬁed that were
unique to the M29 cells. We reasoned that the genes identiﬁed that
were shared between variant cell lines would limit the number of
false positives. However, we also realize that this strategy could also
result in a failure to identify genes driving this process, as each cell
line has a different reversion rate, as well as response to the introduc-
tion of Hnf1a [14,15,18]. Therefore, each variant cell line likely has
distinct defects that lead to loss of liver gene expression.
It has been previously reported that these variant cell lines are
able to revert back to hepatoma cells when positive selection on the
Aprt or Gpt genes is applied [14]. In each case, surviving cells rescued
expression of Hnf4a, Hnf1a and Serpina1 genes. Thus, the robust phe-
notypes of the variant cells do not appear to be ﬁxed, but rather cells
are able to revert to hepatoma phenotypes at low frequency. The re-
sults presented here show that expression levels of over 300 genes
are dramatically affected (~60 of these by greater than 10-fold). We
observed 132 genes that were repressed in all four cell lines, and an
additional 68 genes shared among 3 of 4 cell lines. Genes affected in-
cluded a large set of well-studied liver-enriched genes (e.g. Alb, Fgb,
Ttr, Pck1, Tat, Pah) as well as many genes not previously described
as being liver-speciﬁc. In addition, 6 members of the serpin gene fam-
ily were repressed, as were 11 members of the CYP family proteins
and 7 members of the UDP glycosyltransferase gene superfamily.
Marsden and Fournier [27] showed that the serpin gene cluster
at 14q32.1 contains three liver-speciﬁc serpin genes, SERPINA1,
SERPINA6 and SERPINA10. Deletion of a cluster of DNaseI hypersensi-
tive sites in this locus resulted in loss of expression of each gene and
decreased histone acetylation that suggested extensive remodeling of
the chromosomal region [28]. Each of these genes was repressed
>10-fold in all four variant cell lines tested in the current study, con-
sistent with the idea of common regulatory control of these genes. In
addition, introduction of the HNF4/HNF1α transactivation cascade
into the H11 variant cells resulted in extensive remodeling and re-
expression of an introduced human serpin locus [29]. As described
above, microarray data showed only modest repression on these fac-
tors in the variant cell lines, yet qPCR showed robust repression of
Hnf1a. Other well-known liver-enriched factors, Foxa2 and Cepba,
showed less than 2.5 fold repression in any variant cell line, although
Onecut1 showed strong repression in all variant cell lines.
We screened the panel of genes that were repressed greater than
5-fold in at least two of the four cell variants for reported gene regu-
latory activity. We reasoned that genes responsible for the observed
repression phenotype would likely also be repressed in the variant
cells. Fourteen candidate genes were identiﬁed that encode proteins
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Dppa5, Gas2, Hhex, Igfbp1, Mdk, Onecut1, Rnf125, Sec16b, Stra8 and
Tcfap2b. Each of these genes were moderately to highly expressed
in hepatoma cells (600U–10,000U) but strongly repressed in the var-
iant cell lines. Hhex is a homeodomain transcription factor expressed
in the anterior deﬁnitive endoderm [30] and is required for proper
mammalian development. Loss-of-function Hhex knockout mice die
during embryogenesis with several defects, including altered liver de-
velopment [31]. The role of Igfbp1 has been shown to both disrupt
and promote IGF-1 action [32]. Creg1 antagonizes adenoviral E1A ac-
tivity and has been suggested to affect transcriptional control of cell
growth and differentiation [33], although reports in liver function
have not been described. Bhlhe40 (Dec1/Stra13) is a basic helix–
loop–helix (bHLH) transcriptional repressor widely expressed in
both embryonic and adult tissues and has been reported to strongly
suppress Pepck expression in H4IIE hepatoma cells [34] as well as af-
fect circadian rhythms [35]. Dppa4 and 5 are developmental
pluripotency associated genes reported to be active in embryogene-
sis, including induction of mouse embryonic stem cells into primitive
ectoderm lineage [36,37]. Gas2 is a protein thought to be involved in
growth arrest as well as development [38] and was one of the four
genes (Gas2, Igfbp2, Nr1i3, and Ccne2) that were differentially
expressed in tetraploid and octoploid cells [39]. Mdk (Midkine) is a
heparin-binding growth factor reported to affect the proliferation
and migration of several cell types [40] and has been shown to play
a role in liver regeneration [41]. RNF125 is a ubiquitin ligase that
has also been reported to be a positive regulator of T-cell activation
[42] and to inhibit HIV-1 viral transcription [43]. Stra8 is a retinoic
acid-inducible gene active in early mammalian embryogenesis [44].
Finally, Tfap2b (AP-2 related transcription factor) is a transcription
activator involved in early embryogenesis [45].
We previously reported a genome-wide analysis of gene silencing
in hepatoma×ﬁbroblast whole cell hybrids [22]. We reported ap-
proximately 300 genes that were repressed >5-fold. We noted a
large degree of overlap of genes identiﬁed in the current study of
cell variants, although a comprehensive comparison is not possible
due to the use of different microarray formats. However, certain con-
clusions can be made. First, the majority of well-known markers of
liver function are repressed in both cell systems. The remarkable
numbers of genes that are strongly repressed in both cell models sug-
gest that extensive remodeling occurs upon loss of liver function. No-
tably, only a modest number of candidate genes (Oncecut1, Hhex,
Igfbp1 as well as Hnf1a and Hnf4a if the threshold is lowered to
3-fold) are shared between these two cell model systems. Candidate
genes identiﬁed in the previous study fell into three categories: Wnt
pathway, growth hormone signaling and the HNF network [22]. Can-
didate genes identiﬁed in the current study included 14 genes that
appear to have little in common (see Table 3), except that they appear
to be involved in transcriptional and/or developmental regulatory
pathways.
This suggests that distinct strategies are used to silence gene ex-
pression in these two cell models. Given the very distinct strategies
used to generate cell types with repressed liver gene expression, per-
haps this is not too surprising. However, the majority of the hundreds
of downstream liver-speciﬁc genes are repressed in both model sys-
tems, indicating that the same liver-speciﬁc pathways are impacted
(data not shown).
Our approach was to use rat whole genomemicroarrays to analyze
the well characterized rat hepatoma cells and hepatoma variants to
understand the full extent of gene silencing in cell variants as well
as to identify candidate genes involved in the process. Our results
suggest that gene silencing is extensive, with hundreds of genes
strongly repressed in the variant cells. The ability of HNF1α to acti-
vate expression of 60 genes, most with HNF1a binding sites in their
promoters, suggests that a single factor can cause dramatic repro-
gramming of the variant cells. Testing of additional candidate geneswill be carried out to determine whether other proteins can play a
role in reactivation of the liver phenotype.
In conclusion, whole-genome analysis gene repression in hepato-
ma variant cell lines indicates that distinct gene sets are repressed in
each variant cell line, but that a large degree of overlap is observed.
Genetic rescue experiments have shown that HNF1a can restore
much of the lost liver gene expression. Further testing of candidate
genes is currently being conducted in order to identify genes that
play a critical role in establishing and maintaining hepatic function
in the mammalian liver.
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